PE20120638A1 - Combinaciones farmaceuticas que comprenden danoprevir o una sal del mismo, y ritonavir - Google Patents
Combinaciones farmaceuticas que comprenden danoprevir o una sal del mismo, y ritonavirInfo
- Publication number
- PE20120638A1 PE20120638A1 PE2011001850A PE2011001850A PE20120638A1 PE 20120638 A1 PE20120638 A1 PE 20120638A1 PE 2011001850 A PE2011001850 A PE 2011001850A PE 2011001850 A PE2011001850 A PE 2011001850A PE 20120638 A1 PE20120638 A1 PE 20120638A1
- Authority
- PE
- Peru
- Prior art keywords
- ritonavir
- compound
- danoprevir
- salt
- same
- Prior art date
Links
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 title abstract 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 title abstract 3
- 229960000311 ritonavir Drugs 0.000 title abstract 3
- ZVTDLPBHTSMEJZ-UPZRXNBOSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-UPZRXNBOSA-N 0.000 title 1
- 229950002891 danoprevir Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- -1 R7227 COMPOUND Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE PROTEASA NS3/4A DEL VIRUS DE LA HEPATITIS C TAL COMO EL COMPUESTO R7227 DE FORMULA (I); B) UN INHIBIDOR DE MONOOXIGENASA DEL CITOCROMO P450 TAL COMO RITONAVIR; Y C) UN COMPUESTO ADICIONAL TAL COMO UN INMUNOMODULADOR, UN INHIBIDOR DE POLIMERASA NS5B, ENTRE OTROS; EN DONDE EL RITONAVIR INCREMENTA LA BIODISPONIBILIDAD DEL COMPUESTO R7227. COMPUESTO R7227 DE FORMULA (I): (2R,6S,12Z,13AS,14AR,16AS)-14A-[(CICLOPROPILSULFONIL)CARBAMOIL]-6-({[(2-METIL-2-PROPANIL)OXI]CARBONIL}AMINO)-5,16-DIOXO-1,2,3,5,6,7,8,9,10,11,13A,14,14A,15,16,16A-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1, 2-A][1,4]DIAZACICLOPENTADECIN-2-IL 4-FLUORO-1,3-DIHIDRO-2H-ISOINDOLE-2-CARBOXILATO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17272209P | 2009-04-25 | 2009-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120638A1 true PE20120638A1 (es) | 2012-05-26 |
Family
ID=42236685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001850A PE20120638A1 (es) | 2009-04-25 | 2010-04-22 | Combinaciones farmaceuticas que comprenden danoprevir o una sal del mismo, y ritonavir |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20100272682A1 (es) |
| EP (1) | EP2421527B1 (es) |
| JP (1) | JP5523552B2 (es) |
| KR (1) | KR101471238B1 (es) |
| CN (2) | CN105233249A (es) |
| AR (1) | AR076388A1 (es) |
| AU (1) | AU2010240893B2 (es) |
| BR (1) | BRPI1015147B1 (es) |
| CA (1) | CA2758644C (es) |
| CL (1) | CL2011002643A1 (es) |
| CO (1) | CO6440593A2 (es) |
| CR (1) | CR20110551A (es) |
| DK (1) | DK2421527T3 (es) |
| EC (1) | ECSP11011420A (es) |
| ES (1) | ES2683736T3 (es) |
| HK (1) | HK1215858A1 (es) |
| HR (1) | HRP20181306T1 (es) |
| HU (1) | HUE040182T2 (es) |
| IL (1) | IL215620A (es) |
| LT (1) | LT2421527T (es) |
| MA (1) | MA33212B1 (es) |
| MX (2) | MX2011011105A (es) |
| MY (1) | MY169734A (es) |
| NZ (1) | NZ595917A (es) |
| PE (1) | PE20120638A1 (es) |
| PL (1) | PL2421527T3 (es) |
| PT (1) | PT2421527T (es) |
| RS (1) | RS57501B1 (es) |
| RU (1) | RU2591830C2 (es) |
| SG (1) | SG175328A1 (es) |
| SI (1) | SI2421527T1 (es) |
| TR (1) | TR201809600T4 (es) |
| TW (1) | TWI468160B (es) |
| UA (1) | UA103801C2 (es) |
| WO (1) | WO2010122087A1 (es) |
| ZA (1) | ZA201107421B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110075019A (ko) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EA201490837A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| MX355102B (es) | 2012-01-11 | 2018-04-05 | Abbvie Ireland Unlimited Co | Procesos para hacer los inhibidores de la proteasa del hcv. |
| JP2015522022A (ja) * | 2012-06-27 | 2015-08-03 | アッヴィ・インコーポレイテッド | Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置 |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| SI3137078T1 (sl) * | 2014-05-01 | 2019-08-30 | Eiger Biopharmaceuticals, Inc. | Zdravljenje okužbe s hepatitis delta virusom |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2189721T3 (es) | 1992-12-29 | 2003-07-16 | Abbott Lab | Inhibidores de proteasa retroviral. |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| IL141438A0 (en) | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
| US7169760B2 (en) * | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| KR20050085681A (ko) | 2002-12-16 | 2005-08-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도 |
| JP2007509950A (ja) * | 2003-10-27 | 2007-04-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ処置の組合せ剤 |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
-
2010
- 2010-04-22 ES ES10714883.5T patent/ES2683736T3/es active Active
- 2010-04-22 JP JP2012506491A patent/JP5523552B2/ja active Active
- 2010-04-22 MX MX2011011105A patent/MX2011011105A/es active IP Right Grant
- 2010-04-22 RS RS20180898A patent/RS57501B1/sr unknown
- 2010-04-22 HU HUE10714883A patent/HUE040182T2/hu unknown
- 2010-04-22 PL PL10714883T patent/PL2421527T3/pl unknown
- 2010-04-22 CN CN201510706536.XA patent/CN105233249A/zh active Pending
- 2010-04-22 SI SI201031725T patent/SI2421527T1/sl unknown
- 2010-04-22 PE PE2011001850A patent/PE20120638A1/es active IP Right Grant
- 2010-04-22 RU RU2011142651/15A patent/RU2591830C2/ru active
- 2010-04-22 KR KR1020117027997A patent/KR101471238B1/ko active Active
- 2010-04-22 DK DK10714883.5T patent/DK2421527T3/en active
- 2010-04-22 MY MYPI2011005073A patent/MY169734A/en unknown
- 2010-04-22 HR HRP20181306TT patent/HRP20181306T1/hr unknown
- 2010-04-22 EP EP10714883.5A patent/EP2421527B1/en active Active
- 2010-04-22 BR BRPI1015147-8A patent/BRPI1015147B1/pt active IP Right Grant
- 2010-04-22 MA MA34273A patent/MA33212B1/fr unknown
- 2010-04-22 CA CA2758644A patent/CA2758644C/en active Active
- 2010-04-22 UA UAA201113756A patent/UA103801C2/ru unknown
- 2010-04-22 NZ NZ595917A patent/NZ595917A/en unknown
- 2010-04-22 TW TW99112703A patent/TWI468160B/zh active
- 2010-04-22 TR TR2018/09600T patent/TR201809600T4/tr unknown
- 2010-04-22 SG SG2011077732A patent/SG175328A1/en unknown
- 2010-04-22 PT PT107148835T patent/PT2421527T/pt unknown
- 2010-04-22 LT LTEP10714883.5T patent/LT2421527T/lt unknown
- 2010-04-22 AU AU2010240893A patent/AU2010240893B2/en active Active
- 2010-04-22 MX MX2013013597A patent/MX351185B/es unknown
- 2010-04-22 CN CN2010800181204A patent/CN102413827A/zh active Pending
- 2010-04-22 WO PCT/EP2010/055317 patent/WO2010122087A1/en not_active Ceased
- 2010-04-23 US US12/766,051 patent/US20100272682A1/en not_active Abandoned
- 2010-04-23 AR ARP100101352A patent/AR076388A1/es not_active Application Discontinuation
-
2011
- 2011-10-06 IL IL215620A patent/IL215620A/en active IP Right Grant
- 2011-10-10 ZA ZA2011/07421A patent/ZA201107421B/en unknown
- 2011-10-12 CO CO11135691A patent/CO6440593A2/es active IP Right Grant
- 2011-10-19 CR CR20110551A patent/CR20110551A/es unknown
- 2011-10-24 CL CL2011002643A patent/CL2011002643A1/es unknown
- 2011-10-25 EC EC2011011420A patent/ECSP11011420A/es unknown
-
2016
- 2016-04-05 HK HK16103828.4A patent/HK1215858A1/zh unknown
-
2017
- 2017-01-12 US US15/404,398 patent/US20170119739A1/en not_active Abandoned
-
2018
- 2018-07-11 US US16/033,177 patent/US20180318267A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/842,855 patent/US10918626B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120638A1 (es) | Combinaciones farmaceuticas que comprenden danoprevir o una sal del mismo, y ritonavir | |
| EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
| DOP2011000023A (es) | Compuestos macrociclicos de quinoxalina como inhibidores de la proteasa ns3 de hcv | |
| PE20150202A1 (es) | Compuestos antivirales | |
| CL2011000512A1 (es) | (2r,6s,13as,14ar,16as,z)-n- (ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida y composicion farmaceutica que lo comprende. | |
| GT201300077AA (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas (solicitud de patente fraccionaria de la solicitud no. a-2013-00077) | |
| PE20121432A1 (es) | Combinaciones de un inhibidor especifico de ns5a del hcv e inhibidor de proteasa ns3 del hcv | |
| TW201129370A (en) | Hepatitis C inhibitor compounds | |
| PE20081792A1 (es) | Inhibidores de serina proteasas | |
| MX2009004556A (es) | Inhibidores de la proteasa ns3 del hcv. | |
| CL2012001230A1 (es) | Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c. | |
| EA200900969A1 (ru) | Макроциклические ингибиторы протеазы гепатита с | |
| JO2593B1 (en) | Protease inhibitors NS3 hepatitis C HCV virus | |
| WO2013074386A3 (en) | Hcv ns3 protease inhibitors | |
| PE20090228A1 (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
| CL2013003171A1 (es) | Compuesto macrociclico derivado de prolina inhibidor de la proteasa serina ns3; su composicion farmaceutica; y su uso en el tratamiento de una infeccion viral, en particular una infeccion causada por el virus de la hepatitis c (vhc). | |
| UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
| CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
| NZ609564A (en) | Inhibitors of hepatitis c virus | |
| MX2009009176A (es) | Inhibidores de serina-proteasas. | |
| PE20091164A1 (es) | Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c | |
| CL2013000670A1 (es) | Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv. | |
| ECSP13012552A (es) | Formas en estado sólido de un potente inhibidor del vch. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |